



## **Chimerix to Report Fourth Quarter and Year End 2022 Financial Results and Provide an Operational Update on March 2, 2023**

February 23, 2023

DURHAM, N.C., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on Thursday, March 2, 2023 at 8:30 a.m. ET to report financial results for the fourth quarter and full-year ended December 31, 2022, and to provide a business overview.

To access the live conference call, please dial (646) 307-1963 (domestic) or (800) 715-9871 (international) at least five minutes prior to the start time, and refer to conference ID 9730865. A live audio webcast of the call will also be available on the Investors' section of the Company's website, [www.chimerix.com](http://www.chimerix.com). An archived webcast will be available on the Chimerix website approximately two hours after the event.

### **About Chimerix**

Chimerix is a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The Company's most advanced clinical-stage development program, ONC201, is in development for H3 K27M-mutant glioma.

### **CONTACTS:**

Michelle LaSpaluto  
919 972-7115  
[ir@chimerix.com](mailto:ir@chimerix.com)

Will O'Connor  
Stern Investor Relations  
212-362-1200  
[will@sternir.com](mailto:will@sternir.com)

Nick Lamplough / Dan Moore / Tanner Kaufman  
Joele Frank, Wilkinson Brimmer Katcher  
(212) 355-4449



Source: Chimerix, Inc.